Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Clinical
    • Critical Care
    • Procedures
    • COVID-19
  • Practice Management
    • Quality
    • Public Policy
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Learning Portal
    • The Hospital Leader Blog
    • From SHM
    • SIG Spotlight
    • Chapter Spotlight

An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Clinical
    • Critical Care
    • Procedures
    • COVID-19
  • Practice Management
    • Quality
    • Public Policy
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Learning Portal
    • The Hospital Leader Blog
    • From SHM
    • SIG Spotlight
    • Chapter Spotlight

Lipid Disorders

  • News

    Omega-3s tame inflammation in elderly COVID-19 patients

    October 13, 2021

    Those who received an intravenous infusion had significant decreases from baseline to end of treatment in the neutrophil-to-lymphocyte ratio.

  • 1
    News

    PRESERVED-HF: Dapagliflozin improves physical limitations in patients with HFpEF

    September 14, 2021

    The SGLT2 inhibitor dapagliflozin boosted KCCQ scores and 6-minute walk distance in HFpEF patients in a 324-patient randomized trial.

  • 1
    News

    Two swings, two misses with colchicine, Vascepa in COVID-19

    September 1, 2021

    The study cohorts varied from healthcare and public workers at high risk for infection to individuals already hospitalized with COVID-19.

  • 1
    News

    EMPEROR-Preserved spouts torrent of reports on empagliflozin treatment of HFpEF

    August 31, 2021

    The primary report from EMPEROR-Preserved on using empagliflozin to treat patients with HFpEF arrived with four other analyses published in its wake.

  • 1
    News

    SGLT2 inhibitor use rising in patients with DKD

    August 23, 2021

    Use of SGLT2 inhibitors in patients with type 2 diabetes rose sharply in 2019 and early 2020. GLP-1 RA use also showed recent gains.

  • News

    Empagliflozin gets HFrEF approval from FDA

    August 19, 2021

    The SGLT2 inhibitor empagliflozin (Jardiance) becomes the second agent from this class to get a heart failure indication regardless of diabetes status.

  • 1
    News

    Statins again linked to lower COVID-19 mortality

    July 21, 2021

    Patients hospitalized for COVID-19 who had been taking statins had a substantially lower risk of death and severe outcomes than those who weren’t in a large observational study.

  • 1
    News

    DOACs linked to lower mortality than vitamin K antagonist: 3-year TAVR registry

    July 16, 2021

    Mortality and bleeding advantage favors DOACs over VKA in TAVR patients who are candidates for anticoagulation.

  • 1
    News

    New AHA/ASA guideline on secondary stroke prevention

    May 27, 2021

    Identifying the cause of a first stroke or transient ischemic attack is key to developing strategies to prevent repeat events, the AHA/ASA says in an updated clinical practice guideline.

  • 1
    News

    PARADISE-MI: Sacubitril/valsartan can’t beat ramipril in patients with acute MI

    May 15, 2021

    When treating patients with no history of heart failure within days of an acute myocardial infarction, sacubitril/valsartan showed safety but no clear superiority to ramipril.

1 2 3 … 5Next
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
  • Copyright © 2000-2023 by the Society of Hospital Medicine and related companies. All rights reserved. ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences